IGI Seminar Series – Correction of the Sickle Cell Disease Mutation with CRISPR-Cas9

UCLA project scientist Mark DeWitt discusses a combined IGI, UCLA, and UCSF effort in developing a CRISPR-based clinical product to correct sickle cell disease. Listen to Mark as he describes how his team went from a bench genome-editing protocol to an accepted Investigational New Drug (IND).

IGI Seminar Series - May 4, 2021

Видео IGI Seminar Series – Correction of the Sickle Cell Disease Mutation with CRISPR-Cas9 канала Innovative Genomics Institute – IGI